Analgesics Market Size, Share & Trends Analysis

Analgesics Market Size, Share & Trends Analysis

The global analgesics market is poised for significant growth, driven by the rising prevalence of conditions such as arthritis and osteoarthritis, neuropathic diseases, and cancer. As a result, the market size was valued at USD 38.60 billion in 2022, with an expected compound annual growth rate (CAGR) of 6.02% from 2023 to 2030. Pharmaceutical companies are actively developing novel analgesics to tackle pain management, presenting promising opportunities for market expansion. Recent developments, such as the US launch of several novel pain relief drugs in development phases, underscore this trend. As of October 2022, there were 17 new pain treatments undergoing clinical trials, with 16 of these in phase 3 trials. This convergence of scientific innovation and commercial partnerships is expected to drive market growth over the forecast period.

Request a Free Sample - https://www.theresearchinsights.com/reports/analgesics-market-99/request-sample

The rising incidence of targeted diseases is poised to drive market growth over the forecast period. For example, according to the Centers for Disease Control and Prevention (CDC), approximately 1 in every 4 U.S. adults (23.7%) - around 58.5 million people - are diagnosed with arthritis each year. Notably, arthritis disproportionately affects women compared to men, while its prevalence tends to increase with age.

The rising prevalence of osteoarthritis, fibromyalgia, and gout has led to an increased demand for effective pain management solutions. Many individuals seek relief from chronic joint pain and inflammation through various treatments, including a range of commonly prescribed analgesics such as celecoxib, naproxen, ibuprofen, diclofenac, and etodolac. As a result, the market for these medications is experiencing significant growth driven by the growing need for effective arthritis management solutions.

The growing need for pain management solutions is expected to rise in tandem with the increasing number of surgical procedures performed globally. For instance, according to the National Center for Biotechnology Information (NCBI), approximately 310 million major surgeries are reported annually worldwide; this translates to around 40-50 million in the United States and 20 million in Europe. Furthermore, data from the Australian Commission on Safety and Quality in Health Care indicates that over 2.5 million individuals undergo surgical procedures in both private and public hospitals in Australia each year.

Request a Free Sample

Regulatory bodies worldwide are actively investing in the development of non-addictive alternatives to opioids for effective pain management. The US FDA took significant strides in February 2022, aiming to expedite the creation of non-addictive solutions to combat rising addiction rates. Meanwhile, ACSQHC established a new standard of care in April 2022, focusing on responsible use of opioid analgesics in emergency departments following surgical procedures.

The quest for safe and effective pain relief solutions is driving regulatory bodies to expedite product approvals for innovative analgesic preparations. Ongoing research efforts have focused on creating potent pain relief drugs that minimize the risk of addiction and overdose. In September 2022, Lupin Limited secured U.S. FDA approval for its ANDA diclofenac sodium USP 2% w/w. Similarly, in May 2020, Dr. Reddy's Laboratories announced U.S. FDA clearance for its ELYXYB, designed to manage migraine with or without aura in adult patients.

The growing demand for pain relief medications within our target demographic has created a lucrative market opportunity for manufacturers. As a result, several companies are now entering these markets with their products, with the aim of generating significant revenue. For example, Dr. Reddy's Laboratories successfully reintroduced the over-the-counter version of naproxen sodium tablets in August 2021, which is comparable to Bayer's Aleve, in the U.S. market. This move was driven by its outstanding sales performance in previous quarters.

Drug Type Insights

The non-opioid segment has emerged as a leading force in the analgesics market, accounting for 52.01% of the share in 2022. This significant presence can be attributed to the mounting demand for non-opioid analgesics, driven by their relatively lower risk of adverse effects and strong availability of generic preparations. Additionally, initiatives by private organizations and governments have played a crucial role in promoting the use of non-opioid treatments in pain management. The promising results obtained from clinical trials have also contributed to this growth, as evidenced by Vertex Pharmaceuticals' announcement in March 2022 of positive phase II trial outcomes for its non-opioid candidate VX-548.

The compound medication segment is poised for the most rapid growth over the forecast period, driven by a surge in combination drug adoption. The high efficacy of opioid-combined analgesics, coupled with minimal side effects, has significantly contributed to this trend. Moreover, an increasing awareness of safe analgesic use has further fueled segment expansion through 2030. A notable example is ESTEVE's SEGLENTIS (celecoxib and tramadol hydrochloride) approval in October 2021 by the U.S. FDA, which marks a significant milestone for acute pain management in adults.

Route Of Administration Insights

The oral route has long been the leading distribution channel for analgesics, boasting a substantial market share of 47.88% in 2022. The ease with which analgesic medications can be administered orally, coupled with their non-invasive nature, play significant roles in this segment's success. Furthermore, pharmaceutical companies are intensifying research and development efforts to create novel oral analgesics that minimize side effects and lower the risk of overdose, poised to drive growth through 2030. For example, Tris Pharma’s Phase 2b clinical study of its cebranopadol in December 2022 demonstrated a notable reduction in addictive potential compared to opioids.

The parenteral route of administration dominates market share, poised for significant growth over the forecast period. Factors driving this trend include elevated hospitalization rates linked to chronic conditions and surgeries, rapid onset of action, and enhanced bioavailability of administered products. Furthermore, strong demand for parenteral analgesics in critical care settings and cancer treatment centers is expected to propel segment growth, driven by the need for effective pain management in these high-stakes environments.

Application Insights

The surgical and trauma segment dominated the analgesics market in 2022, accounting for a significant share of 22.71%. This is largely attributed to the growing need for pain management during and post-surgical procedures, as well as an increase in traumatic injuries. Moreover, several initiatives aimed at addressing traumatic events, including the Global Emergency and Trauma Care Initiative, National Child Traumatic Stress Initiative, and others, are anticipated to propel segment growth in the forecast period.

The NSW government reports a significant number of elective surgery procedures annually within its public hospitals, with over 200,000 procedures undertaken every year. To manage post-operative pain effectively, healthcare professionals employ various analgesic options during and after the surgeries. These commonly include potent opioids such as fentanyl, morphine, hydromorphone, alfentanil, as well as non-opioid alternatives like dexmedetomidine, ketamine, ketorolac, and others.

The neuropathic segment is poised for substantial growth over the forecast period, driven by a combination of factors that have contributed to an increase in its lucrative CAGR. The rising prevalence of neuropathic pain has created a significant demand for effective analgesics, fueling the growth of this segment. Furthermore, ongoing research and development efforts aimed at creating novel and more effective treatments for neuropathic disorders are expected to play a pivotal role in driving segment expansion. Notably, as of 2022, numerous investigational analgesics were being explored for use in treating conditions such as neuralgia, back pain, and muscle pain.

Distribution Channel Insights

The retail pharmacies segment has consistently led the analgesics market, accounting for 50.96% of the total revenue in 2022. This segment's success can be attributed to several key factors, including increased accessibility of over-the-counter (OTC) prescriptions, high levels of generic penetration, and a rising number of pain-related prescriptions due to growing incidence rates. Furthermore, the surge in OTC drug launches has further contributed to this segment's growth, with recent examples such as diclofenac, ibuprofen, and ketorolac now available without a prescription.

The online pharmacy market is poised for significant expansion in the coming years, driven by key factors such as high internet penetration rates, the growing trend of e-commerce adoption, heightened awareness about online pharmacies, and competitive pricing through online discounts. Additionally, the increasing popularity of telemedicine globally is expected to fuel segment growth during this projection period.

Regional Insights

In 2022, North America dominated the global analgesic market, accounting for a substantial 31.76% of the revenue share. This significant lead can be attributed to several key factors. Firstly, the presence of prominent players in the region has fostered a competitive landscape that drives innovation and growth. Secondly, substantial investments have been made in research and development (R&D) focused specifically on analgesics, ensuring the region stays at the forefront of medication advancements. The market's upward trajectory can also be linked to the prevalence of prevalent health issues such as musculoskeletal disorders and chronic pain within the population. Furthermore, a lower cost of analgesics in North America plays a vital role in fueling growth in this sector.

The growth of the regional market is further bolstered by the rising number of surgical procedures and government-backed efforts to promote responsible analgesic usage. For example, in 2022, the CDC introduced revised opioid prescribing guidelines aimed at balancing treatment needs with caution, reflecting a growing need for innovative pain management solutions.

The Asia Pacific market is poised for rapid expansion over the forecast period, driven primarily by a combination of factors. The region's substantial burden of chronic diseases, coupled with an aging population and surging economies, are expected to propel growth rates at an unprecedented pace. Furthermore, unmet patient needs and significant investments by leading market players are anticipated to further fuel industry expansion during this time frame.

Key Companies & Market Share Insights

As the global analgesics market continues to evolve, key players are taking strategic steps to enhance their presence. In March 2023, Pfizer Inc. secured U.S. FDA approval for ZAVZPRET, a groundbreaking CGRP receptor antagonist nasal spray designed to tackle acute migraine in adults. This development is poised to propel market growth over the forecast period. Notably, prominent players in the global analgesics market are investing in various initiatives such as new product development, mergers & acquisitions, and partnerships to bolster their market share.

• Bayer AG

• Endo International plc

• Assertio Holdings, Inc.

• Janssen Global Services, LLC

• GSK plc

• AbbVie Inc.

• Novartis AG

• Viatris Inc.

• Teva Pharmaceutical Industries Ltd.

Analgesics Market Report Scope

Global Analgesics Market Report Segmentation

This comprehensive forecast examines revenue growth across global, regional, and country markets, offering in-depth insights into emerging trends within each sub-segment. From 2018 to 2030, our analysis delves into the latest developments shaping the analgesics market, segmented by drug type, route of administration, application, distribution channel, and geographic region, to provide a nuanced understanding of this dynamic industry.

• Drug Type Outlook (Revenue, USD Billion, 2018 - 2030)

  • Opioid

  • Non-opioid

  • Compound Medication

• Route of Administration Outlook (Revenue, USD Billion, 2018 - 2030)

  • Oral

  • Parenteral

  • Transdermal

  • Others

• Application Outlook (Revenue, USD Billion, 2018 - 2030)

  • Musculoskeletal

  • Surgical and Trauma

  • Cancer

  • Neuropathic

  • Migraine

  • Obstetrical

  • Fibromyalgia

  • Pain Due to Burns

  • Dental/Facial

  • Pediatric

  • Others

• Distribution Channel Outlook (Revenue, USD Billion, 2018 - 2030)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

• Regional Outlook (Revenue, USD Billion, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • Kuwait

    • UAE